A Real‐World Multicentre Retrospective Study of Paclitaxel‐Bevacizumab and Maintenance Therapy as First‐Line for HER2‐Negative Metastatic Breast Cancer

Bevacizumab in combination with taxanes in HER2‐negative metastatic breast cancer (MBC) patients has shown improved progression‐free survival (PFS), despite the lack of clear overall survival (OS) benefit. We performed a retrospective analysis to evaluate the impact of paclitaxel‐bevacizumab and of...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:J Cell Physiol
Main Authors: Gamucci, Teresa, Mentuccia, Lucia, Natoli, Clara, Sperduti, Isabella, Cassano, Alessandra, Michelotti, Andrea, Di Lauro, Luigi, Sergi, Domenico, Fabi, Alessandra, Sarobba, Maria G., Marchetti, Paolo, Barba, Maddalena, Magnolfi, Emanuela, Maugeri‐Saccà, Marcello, Rossi, Ernesto, Sini, Valentina, Grassadonia, Antonino, Pellegrini, Domenica, Astone, Antonino, Nisticò, Cecilia, Angelini, Franco, Vaccaro, Angela, Pellegrino, Arianna, De Angelis, Claudia, Palleschi, Michela, Moscetti, Luca, Bertolini, Ilaria, Buglioni, Simonetta, Giordano, Antonio, Pizzuti, Laura, Vici, Patrizia
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2016
Fag:
Original Research Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220933/
https://ncbi.nlm.nih.gov/pubmed/27861874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcp.25685
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker